Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Shorted: Short Interest Down 38.8% in October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 15,751 shares, a decline of 38.8% from the September 30th total of 25,736 shares. Based on an average daily trading volume, of 26,150 shares, the short-interest ratio is presently 0.6 days. Approximately 0.9% of the company’s shares are short sold.

Insiders Place Their Bets

In other news, CEO William Quinn sold 9,132 shares of Bolt Biotherapeutics stock in a transaction on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the transaction, the chief executive officer directly owned 25,384 shares in the company, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,584 shares of company stock valued at $128,361 in the last three months. Corporate insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd purchased a new stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics makes up about 0.0% of Nan Fung Group Holdings Ltd’s portfolio, making the stock its 25th largest holding. Nan Fung Group Holdings Ltd owned approximately 0.26% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 86.70% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Trading Up 3.6%

BOLT opened at $6.59 on Friday. The stock has a market capitalization of $12.72 million, a price-to-earnings ratio of -0.40 and a beta of 1.00. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. The company has a 50-day simple moving average of $4.14 and a 200 day simple moving average of $4.52. Bolt Biotherapeutics has a twelve month low of $3.10 and a twelve month high of $7.78.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. Analysts predict that Bolt Biotherapeutics will post -11.10 EPS for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.

Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.